|
|
||||||||
J Thorac Cardiovasc Surg 2007;134:470-476
© 2007 The American Association for Thoracic Surgery
Surgery for Acquired Cardiovascular Disease |
a Department of Thoracic and Cardiovascular Surgery, West German Heart Center Essen, Essen, Germany
b Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, Essen, Germany
c Department of Anaesthesiology and Intensive Care Medicine, University Hospital Essen, Essen, Germany.
Read at the 79th Scientific Sessions of the American Heart Association, Chicago, Ill, November 12-15, 2006.
Received for publication February 6, 2007; revisions received April 10, 2007; accepted for publication April 16, 2007. * Address for reprints: Matthias Thielmann, MD, Department of Thoracic and Cardiovascular Surgery, West-German Heart Center Essen, University Hospital Essen, Hufelandstraße 55, 45122 Essen, Germany. (Email: matthias.thielmann{at}uni-due.de).
| Abstract |
|---|
|
|
|---|
Methods: Between January 2000 and March 2006, 621 consecutive patients with diabetes mellitus and triple-vessel disease undergoing isolated first-time coronary artery bypass grafting as the primary revascularization procedure (group 1) were evaluated for in-hospital mortality and major adverse cardiac events and compared with 128 patients with diabetes mellitus and triple-vessel disease treated during the same time period with previous percutaneous coronary intervention before coronary artery bypass grafting (group 2).
Results: All-cause in-hospital mortality was 2.9% in group 1 and 7.8% in group 2 (odds ratio, 2.84; 95% confidence interval, 1.19-6.68; P = .02). In-hospital major adverse cardiac events were identified in 6.1% and 14.1% (odds ratio, 2.51; 95% confidence interval, 1.32-4.73; P < .005), respectively. Risk-adjusted multivariate logistic regression analysis of previous percutaneous coronary intervention significantly correlated with in-hospital mortality (odds ratio, 2.87; 95% confidence interval, 1.29-6.37; P = .03) and major adverse cardiac events (odds ratio, 2.54; 95% confidence interval, 1.39-4.62; P = .01). After computed propensity score matching based on 12 major preoperative risk factors to control selection bias, conditional regression analysis confirmed previous percutaneous coronary intervention to be associated with all-cause in-hospital mortality (odds ratio, 2.97; 95% confidence interval, 1.12-7.86; P = .03) and major adverse cardiac events (odds ratio, 2.46; 95% confidence interval, 1.18-5.15; P = .02) in these patients.
Conclusion: Previous percutaneous coronary intervention before coronary artery bypass grafting in patients with diabetes mellitus and triple-vessel disease independently increases the risk for in-hospital mortality and major adverse cardiac events.
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Within the database, patients were coded as having previous stent implant procedures or not. The reported study cohort was selected according to criteria of the Bypass Angioplasty Revascularization Investigation.10
Patients included had diabetes mellitus and triple-vessel coronary artery disease (70% stenosis) at their initial coronary revascularization therapy. Patients were excluded if they had left main stenosis (>50%), were treated within 24 hours of a myocardial infarction, or underwent an emergency, concomitant, or repeat surgical procedure. Patients were classified into one of the 2 groups depending on whether they had no previous PCI procedure (group 1) or a previous PCI procedure as the initial revascularization therapy (group 2) before first-time elective CABG surgery. The association between previous PCI before CABG and postoperative in-hospital patient outcome was analyzed. The study was approved by the institutional review board. All of the patients had previously granted permission for use of their medical records for research purposes.
Study End Points and Definitions
All study end points used in this analysis were prespecified. The primary study end point was all-cause in-hospital mortality. The secondary end point was the major adverse cardiac event (MACE) rate, including perioperative myocardial infarction (PMI), low cardiac output syndrome (LCOS), cardiac death, and sudden cardiac death during the postoperative hospitalization period. An independent review of the medical records of the patients who died after CABG surgery was performed, and cardiac versus noncardiac cause of death was adjudicated.In-hospital death was defined as death after CABG during the index hospitalization. A PMI was considered to have occurred if one of the following diagnostic criteria were present: (1) a cardiac troponin I level of greater than 10.5 ng/mL after CABG, as previously described11
; (2) a creatine kinase–MB level of 3 times greater than the upper normal level; (3) new persistent ST-segment or T-wave changes (Minnesota code 4-1, 4-2, 5-1, 5-2, or 9-2); or (4) the development of new Q-waves (Minnesota code 1-1-1 to 1-2-7). LCOS was defined as a cardiac index of 2.0 L · min–1
· m–2 or less or a systolic arterial pressure of 90 mm Hg or less, despite high-dose inotropic support (intravenous dopamine,
8 µg . kg–1
· min–1; dobutamine,
6 µg . kg–1
· min–1; epinephrine, >0.1 µg . kg–1
· min–1; or norepinephrine, >0.1 µg . kg–1
· min–1). Death was considered cardiac if it was caused by PMI, significant cardiac arrhythmias, or refractory LCOS. Sudden unexpected death occurring without another explanation was defined as sudden cardiac death.
Perioperative Management
Surgical revascularization was performed by using standard techniques in all patients, as previously described.12
Heparin was administered to achieve an activated coagulation time of greater than 400 seconds and protamine to reverse heparin according to standard practice. Patients who were receiving dual-antiplatelet therapy with aspirin and clopidogrel before surgical intervention were perioperatively managed as follows: (1) maintenance of aspirin therapy until surgical intervention and routine intravenous administration of 500 mg of aspirin within 6 hours after surgical intervention followed by 100 mg/d thereafter and (2) discontinuation of clopidogrel for a 2- to 5-day window in accordance with the current American College of Cardiology/American Heart Association guidelines by withdrawing clopidogrel 72 hours before surgical intervention at the earliest and restarting it within 48 hours after CABG at the latest.
Statistical Analysis
Descriptive statistics are summarized for categoric variables as frequencies (percentages) and compared between groups by using the Pearson
2
exact test. Continuous variables, expressed as means ± standard deviation or median and interquartile range (15%–75%) were compared between groups by using the Mann-Whitney U test or the Student t test. Univariate and multivariate logistic regression analyses were performed to identify preoperative independent predictors for in-hospital death and MACEs. Those variables identified by means of univariate regression with a P value of .1 or less for at least 1 study end point were added to the multivariate regression model. A propensity score matching (n:m) was performed to control for selection bias as a result of nonrandom assignment to the groups.13
To be precise, we estimated propensity scores using logistic regression13
based on the following patient characteristics and major preoperative risk factors to calculate propensity scores: age, sex, obesity, hypertension, hyperlipidemia, left ventricular ejection fraction, renal disease, previous myocardial infarction, antiplatelet therapy, chronic obstructive pulmonary disease, peripheral vascular disease, and angina class III or IV. We used the propensity scores for stratification13
; that is, patients with similar propensity scores were matched into 20 sets (strata) of equal size. Such stratification is common in medical research13
and is recommended according to the results of Brookmeyer and colleagues.14
Based on the stratified data, a conditional logistic regression analysis was used.15
All statistical analyses were performed with the SAS System, version 8 (SAS Institute, Inc, Cary, NC).
| Results |
|---|
|
|
|---|
Preoperative characteristics of the patients are shown in Table 1. Patients did not differ according to most of their demographics, risk factors, and comorbidities, except for a significantly higher number of patients with hypertension and a higher number of patients with preexisting renal disease in group 2. Patient groups were also significantly different according to their history of previous myocardial infarctions and of course their history of previous PCI procedures. As a result, more group 2 patients had antiplatelet therapy before surgical intervention with aspirin, clopidogrel, or both compared with group 1 patients. The average time between last PCI and CABG was 8 ± 11 months (Table 1). As a main indication for CABG surgery, preoperative coronary angiography presented 15% of group 2 patients with isolated in-stent restenoses, 25% with isolated de novo coronary artery stenoses, and 60% with combined in-stent restenoses and de novo coronary artery stenoses. According to the type of stent used, 72% of group 2 patients had bare-metal stents, 12% had drug-eluting stents, and 16% had both bare-metal stents and drug-eluting stents. Intraoperative results, such as cardiopulmonary bypass and aortic crossclamp times, number of bypass grafts and distal anastomoses, and mean bypass graft flows, did not differ between the groups.
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Recent randomized controlled trails1-4
and large-scale real-world registries5-7
of PCI versus CABG performed in the current stent era still support CABG surgery as the superior and preferred revascularization strategy, deriving a survival benefit for CABG and reducing the necessity for further coronary reintervention procedures in patients with multivessel disease or left main disease and particularly in patients with diabetes mellitus and triple-vessel disease.16
Although these findings are conterminously reflected in the current American College of Cardiology/American Heart Association guidelines, which favor CABG surgery over PCI in these patients, substantial variability exists in practice patterns among individual hospitals, suggesting a lack of clinical consensus. Thus, in turn, PCI is currently being performed more often in patients with severe multivessel disease and even in patients with diabetes mellitus and triple-vessel disease who were considered unsuitable in the past.17
At the same time, recent randomized clinical trials,1-4
although PCI friendly by enrolling only highly selected patient cohorts,18
indicate that probably more than 20% to 40% of the patients treated by means of PCI with more complex coronary lesions and multivessel disease have symptom recurrence and restenosis, requiring further coronary revascularization therapy. Hence todays CABG surgery is faced with a rapidly and cumulatively increasing number of patients with multivessel disease, in whom previous PCI procedures with coronary stenting have initially been performed before patients are finally referred to CABG surgery.
The clinical importance and prognostic significance of patients with a history of PCI that might be interfering with outcome when surgical treatment is subsequently required have become recognized recently. At first, evidence emerged in the former times of angioplasty, showing that patients with initial percutaneous transluminal coronary angioplasty and subsequently undergoing CABG had a poorer long-term survival.19
There was also recent evidence that PCI itself adversely affects outcome in repeated PCIs20
and also in several clinical studies of noncardiac surgical patients, in whom the risk for major adverse events after surgical intervention significantly increased with previous PCI.21-23
More recently, we demonstrated that multiple PCI procedures before CABG significantly impair patient in-hospital outcome,12
and there is also recent evidence that previous PCI increases the risk of death in the short term,24
as well as the risk of symptom recurrence and MACE rate in the midterm,25
after coronary bypass surgery. Potential underlying pathomechanisms for MACEs after PCI have been identified, such as several independent predictors and risk factors of early and long-term stent thrombosis, including the use of more than one stent, use of long stents, use of stents placed at a bifurcation, a history of stent thrombosis, incomplete revascularization, diabetes mellitus, renal failure, low ejection fraction, and premature antiplatelet therapy discontinuation, especially after implantation of drug-eluting stents.26
Conversely, postoperative blood loss and bleeding complications caused by continuation of antiplatelet therapy might lead to increased transfusion and platelet requirements, which in turn might cause acute stent thrombosis. Furthermore, numerous additional perioperative pathomechanisms among patients with previous PCI undergoing CABG might exist, which have been studied less thoroughly and are as yet largely unknown. There is a growing body of evidence that coronary stents are causing arterial wall injury, leading to dysfunctional and denuded coronary endothelium with chronic inflammatory response and platelet and neutrophil adhesion, which in turn are causing adverse cardiovascular events.27-29
In addition, if the diameter of the stented vessel is less than 2.5 to 3.0 mm, the risk of thrombosis is much higher, and the bypass graft has to be inserted more distally, which in turn adversely affects coronary run-off and the patency rate of the inserted graft.27,30
Although the present study was nonrandomized and retrospective in design and the generalizability of our experience at a single tertiary care medical center might not extend to all CABG-performing clinical centers, as the first study, it clearly indicates that the increasing practice of initial PCI before surgical intervention significantly increases the risk of subsequent CABG in a well-defined risk-adjusted and propensity score-matched subgroup of patients with diabetes mellitus and triple-vessel disease. Further clinical research and multicenter outcome studies are needed to investigate and confirm the short-term and long-term effects of PCI procedures with coronary stenting before CABG surgery.
| Earn CME credits at at http://cme.ctsnetjournals.org
|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Carnero-Alcazar, A. Alswies, E. Villagran Medinilla, L. C. Maroto, J. A. Silva Guisasola, J. Cobiella Carnicer, M. T. Tejerina Sanchez, and J. E. Rodriguez Hernandez Mid-term outcomes after off-pump coronary surgery in patients with prior intracoronary stent Eur J Cardiothorac Surg, December 26, 2011; (2011) ezr210v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Boening, B. Niemann, A. Wiedemann, P. Roth, R.-H. Bodeker, C. Scheibelhut, and M. Schonburg Coronary stenting before coronary artery bypass graft surgery in diabetic patients does not increase the perioperative risk of surgery. J. Thorac. Cardiovasc. Surg., August 1, 2011; 142(2): e53 - e57. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bonaros, D. Vill, D. Wiedemann, K. Fischler, G. Friedrich, O. Pachinger, M. Grimm, and T. Schachner Major risk stratification models do not predict perioperative outcome after coronary artery bypass grafting in patients with previous percutaneous intervention Eur J Cardiothorac Surg, June 1, 2011; 39(6): e164 - e169. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Knapik, D. Ciesla, K. Filipiak, M. Knapik, and M. Zembala Prevalence and clinical significance of elevated preoperative glycosylated hemoglobin in diabetic patients scheduled for coronary artery surgery Eur J Cardiothorac Surg, April 1, 2011; 39(4): 484 - 489. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-M. Stevens, P. Khairy, and A. K. Agnihotri Coronary Artery Bypass Grafting After Recent or Remote Percutaneous Coronary Intervention in the Commonwealth of Massachusetts Circ Cardiovasc Interv, October 1, 2010; 3(5): 460 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Lazar Detrimental effects of coronary stenting on subsequent coronary artery bypass surgery: is there another flag on the field? J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 276 - 277. [Full Text] [PDF] |
||||
![]() |
H. A. Tran, S. D. Barnett, S. L. Hunt, A. Chon, and N. Ad The effect of previous coronary artery stenting on short- and intermediate-term outcome after surgical revascularization in patients with diabetes mellitus. J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 316 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yap, B. P. Yan, E. Akowuah, D. T. Dinh, J. A. Smith, G. C. Shardey, J. Tatoulis, P. D. Skillington, A. Newcomb, M. Mohajeri, et al. Does Prior Percutaneous Coronary Intervention Adversely Affect Early and Mid-Term Survival After Coronary Artery Surgery? J. Am. Coll. Cardiol. Intv., August 1, 2009; 2(8): 758 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mack Does Percutaneous Coronary Intervention Compromise the Outcome of Subsequent Coronary Artery Bypass Grafting? J. Am. Coll. Cardiol. Intv., August 1, 2009; 2(8): 765 - 766. [Full Text] [PDF] |
||||
![]() |
P. Massoudy, M. Thielmann, N. Lehmann, A. Marr, G. Kleikamp, A. Maleszka, A. Zittermann, R. Korfer, M. Radu, A. Krian, et al. Impact of prior percutaneous coronary intervention on the outcome of coronary artery bypass surgery: A multicenter analysis J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 840 - 845. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bonaros, D. Hennerbichler, G. Friedrich, A. Kocher, O. Pachinger, G. Laufer, and J. Bonatti Increased mortality and perioperative complications in patients with previous elective percutaneous coronary interventions undergoing coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 846 - 852. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rao, T. Athanasiou, and J. Chikwe Reply Ann. Thorac. Surg., September 1, 2008; 86(3): 1052 - 1053. [Full Text] [PDF] |
||||
![]() |
R. Bhindi, W. Van Gaal, and L. Testa Perspectives on patients with diabetes mellitus and triple-vessel disease undergoing coronary artery bypass grafting after previous percutaneous coronary intervention. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1400 - 1400. [Full Text] [PDF] |
||||
![]() |
D. P. Taggart Does prior PCI increase the risk of subsequent CABG? Eur. Heart J., March 1, 2008; 29(5): 573 - 575. [Full Text] [PDF] |
||||
![]() |
S. Chocron, R. Baillot, J. L. Rouleau, W. J. Warnica, P. Block, D. Johnstone, M. G. Myers, C. D. Calciu, A. Nozza, P. Martineau, et al. Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study Eur. Heart J., March 1, 2008; 29(5): 673 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rao, R. D. L. Stanbridge, J. Chikwe, J. Pepper, P. Skapinakis, O. Aziz, A. Darzi, and T. Athanasiou Does Previous Percutaneous Coronary Stenting Compromise the Long-Term Efficacy of Subsequent Coronary Artery Bypass Surgery? A Microsimulation Study Ann. Thorac. Surg., February 1, 2008; 85(2): 501 - 507. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |